<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01745822</url>
  </required_header>
  <id_info>
    <org_study_id>U01HD071889</org_study_id>
    <secondary_id>U01HD071889</secondary_id>
    <nct_id>NCT01745822</nct_id>
  </id_info>
  <brief_title>Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand</brief_title>
  <acronym>iTAP</acronym>
  <official_title>Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic hepatitis B (CHB) infection is complicated by cirrhosis and liver cancer. In&#xD;
      Thailand, 7% of adults are chronically infected by Hepatitis B virus (HBV). The risk of&#xD;
      perinatal transmission of HBV is about 12% when a mother has a high HBV load in her plasma,&#xD;
      even if her infant receive specific immunoglobulin and vaccine.&#xD;
&#xD;
      The hypothesis of this study is that a potent antiviral, tenofovir, can decrease HBV load in&#xD;
      HBV infected pregnant women and therefore reduce the risk of perinatal transmission/ Pregnant&#xD;
      women participating in this study will receive tenofovir or placebo during the last trimester&#xD;
      of pregnancy and two months postpartum. The risk of perinatal transmission will be compared&#xD;
      between the two groups.&#xD;
&#xD;
      The results of the study will help define policy to manage HBV infected pregnant women to&#xD;
      prevent perinatal transmission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, placebo controlled, double blind, randomized clinical trial to assess&#xD;
      the efficacy and safety of tenofovir disoproxil fumarate (TDF) given from 28 weeks' gestation&#xD;
      until 2 months postpartum to pregnant women with Hepatitis B (HB) virus (HBV) chronic&#xD;
      infection and positive for HB s and e antigen to prevent perinatal transmission of HBV to&#xD;
      their infants. All infants will receive HBV passive (HB specific immunoglobulin) and active&#xD;
      (vaccine) immunization.&#xD;
&#xD;
      Chronic hepatitis B (CHB) infection is complicated by cirrhosis and hepatocellular carcinoma&#xD;
      (HCC), the 10th leading cause of death worldwide.&#xD;
&#xD;
      In 2011, about 7% of adults in Thailand were HBsAg carriers. Infant hepatitis B (HB)&#xD;
      immunization and HB immune globulin (HBIg) administered at birth effectively prevent most&#xD;
      mother-to-child transmission (MTCT) of HBV. However, about 12% of mothers with high load of&#xD;
      HBV transmit the virus to their infants, despite active and passive immunization.&#xD;
&#xD;
      Studies have suggested that antiviral treatment at the end of pregnancy and during early&#xD;
      postpartum can reduce the risk of transmission to the child. A potential limitation to this&#xD;
      approach is the risk of hepatic disease exacerbation following discontinuation of antiviral&#xD;
      treatment postpartum, and this risk has not been properly evaluated. No randomized clinical&#xD;
      trials have adequately demonstrated the efficacy and safety of maternal antiviral treatment&#xD;
      the prevention of mother to child transmission of HBV. This is the reason why this approach&#xD;
      is not currently recommended by the Associations for the Study of Liver Diseases.&#xD;
&#xD;
      We hypothesize that a potent antiviral, tenofovir, can decrease HBV viral load in HBV&#xD;
      infected pregnant women and therefore reduce the risk of perinatal transmission, before&#xD;
      infants are definitely protected by passive-active immunization. We also hypothesize that&#xD;
      only moderate exacerbations of liver disease will be observed after discontinuation of a&#xD;
      short antiviral course (5 months). While the primary objective of the study is to assess the&#xD;
      efficacy of tenofovir versus placebo for the prevention of perinatal transmission, an&#xD;
      important secondary objective is the assessment of the risk of postpartum hepatic disease&#xD;
      exacerbation.&#xD;
&#xD;
      Within 2 years, 328 women and their infants will be enrolled from public hospitals in&#xD;
      Thailand and randomized to receive either tenofovir disoproxil fumarate or matching placebo&#xD;
      from 28 weeks of pregnancy until 2 months postpartum. Mothers and infants will be followed&#xD;
      until one year postpartum.&#xD;
&#xD;
      The primary endpoint will be the detection of HBsAg and HBV DNA in infants at six months of&#xD;
      life. An interim analysis will be conducted when half of the outcomes are available.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Infants With Hepatitis B Infection at 6 Months of Age</measure>
    <time_frame>6 months of age</time_frame>
    <description>Infection is defined as a HBsAg positive test confirmed by detectable HBV DNA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>from enrollment (28 weeks' gestation) to 12 months postpartum</time_frame>
    <description>Occurrence of maternal and infant adverse events, including maternal and infants Serious Adverse Events (as defined by the International Conference on Harmonization Good Clinical Practice) and NIH Division of AIDS grade 3/4 signs and symptoms, regardless of their relatedness to the study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Flares After Study Treatment Interruption</measure>
    <time_frame>Following planned discontinuation of study treatment up to 12 months postpartum</time_frame>
    <description>Flare, or acute exacerbation of hepatitis B, after study treatment interruption is defined as an Alanine Aminotransferase plasma level above 300 IU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Infants With Hepatitis B Infection at or After 6 Months Through 12 Months of Age</measure>
    <time_frame>at or after 6 months through 12 months of age</time_frame>
    <description>Infants will be considered HBV infected if at any time point at or after 6 months through 12 months of age, a sample tests positive for HBsAg and HBV DNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight, Height and Head Circumference for Age</measure>
    <time_frame>assessed at 6 months and 12 months of age, 6 months reported</time_frame>
    <description>Weight, length/height and head circumference WHO Z scores are measures of relative weight, height and head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">654</enrollment>
  <condition>Hepatitis B Chronic Infection</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Tenofovir disoproxil fumarate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenofovir disoproxil fumarate, 300 mg tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo (of tenofovir disoproxil fumarate)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir disoproxil fumarate</intervention_name>
    <description>administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
    <arm_group_label>Tenofovir disoproxil fumarate</arm_group_label>
    <other_name>Viread</other_name>
    <other_name>TDF</other_name>
    <other_name>tenofovir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Negative Human Immunodeficiency Virus (HIV) serology&#xD;
&#xD;
          -  Positive HBsAg and hepatitis B e antigen (HBeAg) tests&#xD;
&#xD;
          -  Gestational age of 28 weeks (+ or - 10 days) as determined by obstetrician&#xD;
&#xD;
          -  Alanine Aminotransferase (ALT)≤30 U/L, confirmed ≤60 U/L on a subsequent blood draw&#xD;
&#xD;
          -  Agreeing to bring their infants at the planned study visits at one study site until&#xD;
             one year after delivery and to inform the site investigators if they plan to move to&#xD;
             another place and not be able to return to the clinic.&#xD;
&#xD;
          -  Understanding the need for adequate infant immunization and agreeing to the blood&#xD;
             draws from their infants and the need for close follow up to manage possible&#xD;
             exacerbation of hepatitis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of tenofovir treatment at any time, or any other anti-HBV treatment during the&#xD;
             current pregnancy&#xD;
&#xD;
          -  Creatinine clearance &lt;50 ml/min, calculated using the Cockcroft-Gault formula&#xD;
&#xD;
          -  Dipstick proteinuria&gt;1+ (&gt;30 mg/dL) or normoglycemic glucosuria confirmed on two&#xD;
             separate occasions&#xD;
&#xD;
          -  Positive serology for Hepatitis C infection less than 12 months prior to enrollment&#xD;
&#xD;
          -  Evidence of pre-existing fetal anomalies incompatible with life&#xD;
&#xD;
          -  Any concomitant condition or treatment that, in the view of the clinical site&#xD;
             investigator, would contraindicate participation or satisfactory follow up in the&#xD;
             study.&#xD;
&#xD;
          -  Concurrent participation in any other clinical trial without written agreement of the&#xD;
             two study teams&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gonzague Jourdain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recherche pour le Developpement</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mae Chan Hospital</name>
      <address>
        <city>Mae Chan</city>
        <state>Chiangrai</state>
        <zip>57110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banglamung Hospital</name>
      <address>
        <city>Bang Lamung</city>
        <state>Chon Buri</state>
        <zip>20150</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maharat Nakhon Ratchasima Hospital</name>
      <address>
        <city>Nakhon Ratchasima</city>
        <state>Nakhon Ratchasrima</state>
        <zip>30000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Kham Hospital</name>
      <address>
        <city>Chiang Kham</city>
        <state>Phayao</state>
        <zip>56110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhumibol Adulyadej Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10220</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nopparat Rajathanee Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10230</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prapokklao Hospital</name>
      <address>
        <city>Chanthaburi</city>
        <zip>22000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Promotion Center Region 10</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50100</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nakornping Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50180</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiangrai Prachanukroh Hospital</name>
      <address>
        <city>Chiang Rai</city>
        <zip>57000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonburi Regional Hospital</name>
      <address>
        <city>Chon Buri</city>
        <zip>20000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khon Kaen Hospital</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lampang Hospital</name>
      <address>
        <city>Lampang</city>
        <zip>52000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lamphun Hospital</name>
      <address>
        <city>Lamphun</city>
        <zip>51000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phayao Provincial Hospital</name>
      <address>
        <city>Phayao</city>
        <zip>56000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutprakarn Hospital</name>
      <address>
        <city>Samut Prakan</city>
        <zip>10280</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samutsakhon Hospital</name>
      <address>
        <city>Samut Sakhon</city>
        <zip>74000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Jourdain G, Ngo-Giang-Huong N, Cressey TR, Hua L, Harrison L, Tierney C, Salvadori N, Decker L, Traisathit P, Sirirungsi W, Khamduang W, Bowonwatanuwong C, Puthanakit T, Siberry GK, Watts DH, Murphy TV, Achalapong J, Hongsiriwon S, Klinbuayaem V, Thongsawat S, Chung RT, Pol S, Chotivanich N. Prevention of mother-to-child transmission of hepatitis B virus: a phase III, placebo-controlled, double-blind, randomized clinical trial to assess the efficacy and safety of a short course of tenofovir disoproxil fumarate in women with hepatitis B virus e-antigen. BMC Infect Dis. 2016 Aug 9;16:393. doi: 10.1186/s12879-016-1734-5.</citation>
    <PMID>27506549</PMID>
  </reference>
  <results_reference>
    <citation>Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Tierney C, Cressey TR, Achalapong J, Siberry GK, Nelson NP, and Chotivanich N. TDF to prevent perinatal hepatitis B virus transmission: a randomized trial (iTAP). Conference on Retroviruses and Opportunistic Infections (CROI) Abstract 584LB; 2017 February 13; Seattle, WA, USA. http://www.croiconference.org/sessions/tdf-prevent-perinatal-hepatitis-b-virus-transmission-randomized-trial-itap</citation>
  </results_reference>
  <results_reference>
    <citation>Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, Salvadori N, Cressey TR, Sirirungsi W, Achalapong J, Yuthavisuthi P, Kanjanavikai P, Na Ayudhaya OP, Siriwachirachai T, Prommas S, Sabsanong P, Limtrakul A, Varadisai S, Putiyanun C, Suriyachai P, Liampongsabuddhi P, Sangsawang S, Matanasarawut W, Buranabanjasatean S, Puernngooluerm P, Bowonwatanuwong C, Puthanakit T, Klinbuayaem V, Thongsawat S, Thanprasertsuk S, Siberry GK, Watts DH, Chakhtoura N, Murphy TV, Nelson NP, Chung RT, Pol S, Chotivanich N. Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med. 2018 Mar 8;378(10):911-923. doi: 10.1056/NEJMoa1708131.</citation>
    <PMID>29514030</PMID>
  </results_reference>
  <results_reference>
    <citation>Jourdain G, Harrison LJ, Ngo-Giang-Huong N, Cressey TR, Decker L, Tierney C, Achalapong J, Kanjanavikai P, Luvira A, Srirompotong U, Murphy TV, Nelson N, Siberry GK, Pol S, for the iTAP Study Group. iTAP trial: maternal and infant efficacy and safety results 12 months after delivery. CROI, 4-7 March 2018, Boston, USA. #1316, Oral Presentation O-11</citation>
  </results_reference>
  <results_reference>
    <citation>Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Kourtis A, Bulterys M, Siberry GK, Jourdain G. TDF prophylaxis for PMTCT of HBV: effect on maternal and infant bone mineral density. CROI, 4-7 March 2018, Boston, USA. #1174. Poster and Themed Discussion TD-09</citation>
  </results_reference>
  <results_reference>
    <citation>Cressey TR, Harrison L, Achalapong J, Kanjanavikai P, Patamasingh Na Ayudhaya O, Liampongsabuddhi P, Siriwachirachai T, Putiyanun C, Suriyachai P, Tierney C, Salvadori N, Chinwong D, Decker L, Tawon Y, Murphy TV, Ngo-Giang-Huong N, Siberry GK, Jourdain G; iTAP Study Team. Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus. Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01686-18. doi: 10.1128/AAC.01686-18. Print 2018 Dec.</citation>
    <PMID>30275094</PMID>
  </results_reference>
  <results_reference>
    <citation>Salvadori N, Fan B, Teeyasoontranon W, Ngo-Giang-Huong N, Phanomcheong S, Luvira A, Puangsombat A, Suwannarat A, Srirompotong U, Putiyanun C, Cressey TR, Decker L, Khamduang W, Harrison L, Tierney C, Shepherd JA, Kourtis AP, Bulterys M, Siberry GK, Jourdain G. Maternal and Infant Bone Mineral Density 1 Year After Delivery in a Randomized, Controlled Trial of Maternal Tenofovir Disoproxil Fumarate to Prevent Mother-to-child Transmission of Hepatitis B Virus. Clin Infect Dis. 2019 Jun 18;69(1):144-146. doi: 10.1093/cid/ciy982.</citation>
    <PMID>30924492</PMID>
  </results_reference>
  <results_reference>
    <citation>Ngo-Giang-Huong N, Salvadori N, Khamduang W, Cressey TR, Harrison LJ, Decker L, Tierney C, Jullapong A, Murphy TV, Nelson N, Siberry GK, Chung RT, Pol S, Jourdain G. Hepatitis B virus DNA level changes in HBeAg+ pregnant women receiving TDF for PMTCT. Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, WA, 4-7 Mar 2019</citation>
  </results_reference>
  <results_reference>
    <citation>Bukkems V, Smolders E, Jourdain G, Hawkins D, Achalapong J, Kanjanavikai P, Taylor G, Prommas S, Burger D, Colbers A, Cressey TR, for the iTAP Study Team &amp; PANNA network. Tenofovir plasma concentrations in pregnant women: comparison of hepatitis B and HIV-infected patients. 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis &amp; Other Antiviral Drugs. Noordwijk, the Netherlands, 14-16-May 2019</citation>
  </results_reference>
  <results_reference>
    <citation>Jourdain G, Traisathit P, Salvadori N, Wangsaeng N, Khamduang W, Ngo-Giang-Huong N, for the iTAP Study Group. Immunization response in infants born to HBsAg+ and HBeAg+ mothers receiving TDF (ID 3681). Conference on Retroviruses and Opportunistic Infections (CROI), Hynes Convention Center, USA, 8-11 Mar 2020, Virtual Conference</citation>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2012</study_first_posted>
  <results_first_submitted>April 28, 2020</results_first_submitted>
  <results_first_submitted_qc>February 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 5, 2021</results_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>GONZAGUE JOURDAIN</investigator_full_name>
    <investigator_title>Chargé de recherches</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis B sAg</keyword>
  <keyword>Hepatitis B eAg</keyword>
  <keyword>pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Pending completion of analysis planned in the protocol</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://dash.nichd.nih.gov/study/17511</doc_url>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 20, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT01745822/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 19, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT01745822/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Enrollment Dates: January 8, 2013 to August 19, 2015 in 17 hospital based antenatal care and pediatrics departments in Thailand</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Tenofovir Disoproxil Fumarate</title>
          <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="331">168 mothers and 163 infants</participants>
                <participants group_id="P2" count="323">163 mothers and 160 infants</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="331"/>
                <participants group_id="P2" count="323"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Mothers only</population>
      <group_list>
        <group group_id="B1">
          <title>Tenofovir Disoproxil Fumarate</title>
          <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
            <count group_id="B2" value="163"/>
            <count group_id="B3" value="331"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.5" lower_limit="22.6" upper_limit="29.1"/>
                    <measurement group_id="B2" value="26.7" lower_limit="23.5" upper_limit="30.5"/>
                    <measurement group_id="B3" value="26.1" lower_limit="22.9" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="331"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age at enrollment</title>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.3" lower_limit="27.9" upper_limit="28.6"/>
                    <measurement group_id="B2" value="28.1" lower_limit="27.9" upper_limit="28.6"/>
                    <measurement group_id="B3" value="28.3" lower_limit="27.9" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Infants With Hepatitis B Infection at 6 Months of Age</title>
        <description>Infection is defined as a HBsAg positive test confirmed by detectable HBV DNA</description>
        <time_frame>6 months of age</time_frame>
        <population>Participants in the primary analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Infants With Hepatitis B Infection at 6 Months of Age</title>
          <description>Infection is defined as a HBsAg positive test confirmed by detectable HBV DNA</description>
          <population>Participants in the primary analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Adverse Events</title>
        <description>Occurrence of maternal and infant adverse events, including maternal and infants Serious Adverse Events (as defined by the International Conference on Harmonization Good Clinical Practice) and NIH Division of AIDS grade 3/4 signs and symptoms, regardless of their relatedness to the study treatment.</description>
        <time_frame>from enrollment (28 weeks' gestation) to 12 months postpartum</time_frame>
        <population>Mother-infant pairs</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Events</title>
          <description>Occurrence of maternal and infant adverse events, including maternal and infants Serious Adverse Events (as defined by the International Conference on Harmonization Good Clinical Practice) and NIH Division of AIDS grade 3/4 signs and symptoms, regardless of their relatedness to the study treatment.</description>
          <population>Mother-infant pairs</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="323"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Maternal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="168"/>
                    <count group_id="O2" value="163"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infant</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="161"/>
                    <count group_id="O2" value="160"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Flares After Study Treatment Interruption</title>
        <description>Flare, or acute exacerbation of hepatitis B, after study treatment interruption is defined as an Alanine Aminotransferase plasma level above 300 IU/mL</description>
        <time_frame>Following planned discontinuation of study treatment up to 12 months postpartum</time_frame>
        <population>Women who had delivered</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Flares After Study Treatment Interruption</title>
          <description>Flare, or acute exacerbation of hepatitis B, after study treatment interruption is defined as an Alanine Aminotransferase plasma level above 300 IU/mL</description>
          <population>Women who had delivered</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Infants With Hepatitis B Infection at or After 6 Months Through 12 Months of Age</title>
        <description>Infants will be considered HBV infected if at any time point at or after 6 months through 12 months of age, a sample tests positive for HBsAg and HBV DNA</description>
        <time_frame>at or after 6 months through 12 months of age</time_frame>
        <population>infants until 12 months of age</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Infants With Hepatitis B Infection at or After 6 Months Through 12 Months of Age</title>
          <description>Infants will be considered HBV infected if at any time point at or after 6 months through 12 months of age, a sample tests positive for HBsAg and HBV DNA</description>
          <population>infants until 12 months of age</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight, Height and Head Circumference for Age</title>
        <description>Weight, length/height and head circumference WHO Z scores are measures of relative weight, height and head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.</description>
        <time_frame>assessed at 6 months and 12 months of age, 6 months reported</time_frame>
        <population>infants at 6 months of age</population>
        <group_list>
          <group group_id="O1">
            <title>Tenofovir Disoproxil Fumarate</title>
            <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
          </group>
        </group_list>
        <measure>
          <title>Weight, Height and Head Circumference for Age</title>
          <description>Weight, length/height and head circumference WHO Z scores are measures of relative weight, height and head circumference adjusted for child age and sex. The Z-score indicates the number of standard deviations away from a reference population in the same age range and with the same sex. A Z-score of 0 is equal to the mean. Negative numbers indicate values lower than the mean and positive numbers indicate values higher than the mean.</description>
          <population>infants at 6 months of age</population>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weight for age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.1"/>
                    <measurement group_id="O2" value="-0.2" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Length for age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.2"/>
                    <measurement group_id="O2" value="-0.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head circumference for age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.1"/>
                    <measurement group_id="O2" value="-0.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From enrollment (28 weeks' gestation) to 12 months postpartum</time_frame>
      <desc>Adverse event information was collected using the same definitions of adverse event and serious adverse event as the clinicaltrials.gov definitions. Only serious adverse events and other (not including serious) Grade 3 or 4 adverse events are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Tenofovir Disoproxil Fumarate</title>
          <description>tenofovir disoproxil fumarate, 300 mg tablets&#xD;
tenofovir disoproxil fumarate: administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo (of tenofovir disoproxil fumarate)&#xD;
placebo: administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose-6-phosphate dehydrogenase deficiency</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Hemivertebra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Multiple congenital abnormalities</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Talipes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia neonatal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Endometritis decidual</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Omphalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Treponema test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Jaundice neonatal</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Meconium aspiration syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Neonatal asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Neonatal respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Transient tachypnoea of the newborn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent foetal circulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Neutrophil count abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Breech presentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Low birth weight baby</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
              <event>
                <sub_title>Retained placenta or membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="323"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gonzague Jourdain</name_or_title>
      <organization>French National Research Institute for Sustainable Development (IRD)</organization>
      <phone>+66818830065</phone>
      <email>gonzague.jourdain@ird.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

